American visceral leishmaniasis (AVL) is associated with the absence of lymphocyte proliferative responses and interleukin (IL)-2 and interferon-y (IFN-y) production upon stimulation with Leishmania antigen. In contrast, cure of AVL is associated with restoration of these T cell functions. In the present study, the ability of IL-12, a cytokine that acts on NK and T cells to restore cellular immune responses in AVL, was evaluated. Participants of the study included 12 patients with AVL and 7 subjects cured of AVL. The [3H]thymidine uptake and IFN-y production in cultures of peripheral blood mononuclear cells (from AVL patients) stimulated with Leishmaniachagasi antigen were 882 ± 1393 cpm and zero, respectively. Addition of IL-12 enhanced the proliferative response to 5097 ± 6429 cpm (P < .001) and IFN-y production to 305 ± 325 pglmL (P < .01). IL-12 also restored cytotoxic activity against the K562 cell line. These results indicate that IL-12 has an important role in the regulation of the cellular immune response in human leishmaniasis.
American visceral leishmaniasis (AVL) is associated with the absence of lymphocyte proliferative responses and interleukin (IL)-2 and interferon-y (IFN-y) production upon stimulation with Leishmania antigen. In contrast, cure of AVL is associated with restoration of these T cell functions. In the present study, the ability of IL-12, a cytokine that acts on NK and T cells to restore cellular immune responses in AVL, was evaluated. Participants of the study included 12 patients with AVL and 7 subjects cured of AVL. The [3H]thymidine uptake and IFN-y production in cultures of peripheral blood mononuclear cells (from AVL patients) stimulated with Leishmaniachagasi antigen were 882 ± 1393 cpm and zero, respectively. Addition of IL-12 enhanced the proliferative response to 5097 ± 6429 cpm (P < .001) and IFN-y production to 305 ± 325 pglmL (P < .01). IL-12 also restored cytotoxic activity against the K562 cell line. These results indicate that IL-12 has an important role in the regulation of the cellular immune response in human leishmaniasis.
American visceral leishmaniasis (AVL) is a systemic protozoan infection caused by Leishmania chagasi, an intracellular parasite that infects and multiplies in macrophages. Monocyte and T cell defects have been associated with Leishmania infection. Macrophages infected with leishmania have decreased ability to express MHC class II molecules [1] and produce interleukin (IL)-12 [2] . In patients with AVL, IL-2 and interferon (IFN)-y production are absent from supernatants of mononuclear cells stimulated with Leishmania antigen [3] . Furthermore, NK cell activity is deficient in AVL patients [4] . Since Th2 cell activation may be involved in progression of AVL [5] and IFN-y production is associated with the ability to control Leishmania infection [6] , the aim of the present study was to evaluate the ability of IL-12 to restore in vitro lymphoproliferative responses, IFN-y production, and NK cell activity following stimulation with Leishmania antigen.
Material and Methods
Patients. Participants included 12 patients with AVL. In all cases, amastigote forms of leishmaniae were detected in Giemsa-stained spleen or bone marrow aspirates. All immunologic studies were done prior to therapy. As a control, 7 subjects cured of AVL were studied.
Leishmania antigen. L. chagasi mammalian Homo sapiens (MHOM Ba 62) antigen was prepared by freeze-thaw lyses. After sonication, the lysate was centrifuged (12,000 g) for 20 min, the supernatant was collected, and protein content was determined by the Lowry method.
Lymphocyte culture, proliferation, and cytokine assays. Peripheral blood mononuclear cells (PBMC) were obtained from venous blood layered over a ficoll-hypaque gradient (lymphocyte separation medium; Organon Teknika, Durham, NC). For in vitro proliferation, 2 X 10 5 cells/well were, cultured in RPMI 1640 (Life Technologies GIBCD BRL, Grand Island, NY) supplemented with penicillin, streptomycin, and 10% heat-inactivated normal AB human serum in 96-well flat-bottomed plates. Cells were stimulated with 5 J,lg/mL L. chagasi antigen in the presence (10-500 U/mL) or absence of recombinant human IL-12. Recombinant human IL-10 (10 ng/mL; DNAX Research Institute) was used as stated. Anti-IL-1O (250 J,lg/mL), monoclonal antibody (MAb), and rat IgGI (GL-I13) isotype control (DNAX) were also added to some cultures. After 5 days, cells were pulsed with 1 Ci of eH]thymidine for the final 6 h of culture. Data are given as mean ± SE counts per minute (cpm) of triplicate cultures or as stimulation index, calculated by dividing the cpm of stimulated culture by the cpm of unstimulated culture.
For determination of cytokine production, PBMC (3 X 106/mL) in complete RPMI were stimulated with L. chagasi antigen (10 J,lg/ mL) with (10-500 U/mL) or without IL-12. In some experiments, recombinant IL-I 0 (10 ng/mL) was also added to cultures. Supernatants were collected at 72 h, and IFN-y levels were determined by ELISA using a sandwich technique. ]sodium chromate for 30 min at 37°C. After being washed, cells were resuspended in RPMI 1640 with 10% fetal calf serum. Aliquots (2 X 10 3 cells/well) were incubated with different numbers of effector cells (effector-to-target [E:T] ratio, 3:1 to 100:1) in round-bottomed plates for 4 h at 37°C. Supernatants were harvested and radioactivity was counted using a gamma counter (model 5500; Beckmann, Fullerton, CA). The percent specific lysis was calculated using the following formula: 100 X [(experimental release -spontaneous release)/(maximum release -spontaneous release)] for a mean of triplicate wells. antigen. The cpm in cultures with medium alone was 403 ± 627 and with IL-12 alone was 549 ± 433. In a dose-response curve (data not shown), the enhancement observed with IL-12 at concentrations of 100 and 500 U/mL was similar to that observed at 10 U/mL. The mean IFN-y level in lymphocyte cultures (of 9 patients) stimulated with L. chagasi antigen was zero. IL-12 increased IFN-y levels to 305 ± 325 pg/mL (P < .01). IFN-y levels in cultures with IL-12 alone were 24 ± 13 pg/mL. The amount of IFN-y production in cultures containing leishmania antigen and IL-12 was similar (P > .05) to that produced by lymphocytes from subjects cured of AVL (498 ± 428 pg/mL).
The role ofIL-l 0 in modulating the immune response mediated by IL-12.
Anti -IL-l 0 MAb restores lymphocyte proliferation and IFN-y production in response to leishmania antigen in patients with AVL [7] . When the enhanced lymphocyte proliferation and IFN-y production mediated by anti -IL-l 0 MAb were compared with those observed with IL-12, IL-12 was shown to be more potent (at least twice as much as the [9, 10] , restored IFN-y production and lymphocyte proliferation. These results confirm the observation by Ghalib et al. [2] in patients with visceral leishmaniasis from Sudan. In addition, IL-12 increased cellular cytotoxicity, a function that is also suppressed in visceral leishmaniasis [4] .
There are indications in vitro of the activity of lytic cells against macrophages parasitized by leishmaniae [11] . Since the main cell responsible for the cytotoxicity against K562 cells is the NK cell and cytotoxic response in this study was enhanced even in cultures without Leishmania antigen, it is conceivable that the main effect of IL-12 was on NK cells. In fact, IL-12 is the most important NK cell stimulatory factor and induces accumulation ofperforin mRNA in most NK cells [12] . In the case of restoration of proliferative response and IFN-1" production, we observed that both NK cells and T cells participated. First, IL-12 restored lymphocyte proliferation, a function related predominantly to T cells; second, proliferation and IFN-y production were predominantly observed in cultures containing both IL-12 and leishmania antigens. It is likely that in this situation, IL-12 and IFN-y improved antigen presentation and, consequently, T cell activation. Then IL-12 acting directly in activated T cells induced lymphocyte proliferation and cytokine production.
Marked expression ofmRNA for IL-l 0 has been documented in patients with visceral leishmaniasis, and the in vitro production of IFN-y and lymphocyte proliferation can be restored by anti -IL-1 0 MAb [7] . IL-1O down-regulates macrophage activity and inhibits IFN-y production by human lymphocytes by suppression ofIL-12 synthesis in accessory cells [13] . Here we show that IL-l 0 abrogates the enhancement of the lymphocyte proliferation and IFN-y production mediated by IL-12. We have previously shown [7l that IL-1O suppressed IFN-y production in subjects cured of visceral leishmaniasis, and others have shown that anti -IL-12 abrogates the IFN -1"production observed when anti-IL-1O is added to PBMC cultures stimulated with L. chagasi antigen [2] . These data indicate that IL-10 plays a major role in the suppression of T cell responses and NK cell activity in visceral leishmaniasis. This suppression can be caused by inhibition of IL-12 synthesis at the accessory cell level and by suppression of cytokine production at the T cell level.
IL-12 plays a crucial role in the resolution of cutaneous leishmaniasis in mice, initiating a Thl cell response that is essential for inducing a protective host immune response; IL-12 also decreases the parasite burden in mice infected with Leishmania donovani [14] . Since control of intracellular infection is related to the ability of macrophages to produce IL-12, which then stimulates IFN-y production, these cytokines are strong candidates as therapeutic agents in leishmaniasis. In fact, there is evidence in both cutaneous and visceral leishmaniasis that IFN-y, in association with pentavalent antimony, induces healing of patients who were previously refractory to antimo- IL-12 induces cytotoxic activity in A VL patients. The functional activity of NK cells is impaired in visceral leishmaniasis [4] . The effect of IL-12 on the cytotoxic activity in PBMC from 5 AVL patients is shown in figure 2 . The results are expressed as percent lysis. The addition of 500 U/mL of IL-12 enhanced cytotoxic activity at four E:T ratios tested (P < .05).
The major immunologic dysfunction in patients with visceral leishmaniasis is the inability of T cells to produce IL-2 and IFN-y upon stimulation with Leishmania antigen and the inability of lymphocytes to activate macrophages to kill leishmaniae [3, 8] . These abnormalities allow parasites to multiply and contribute to the pathogenesis of the disease. In contrast, lymphocyte proliferation in response to leishmania antigen and IFN-y production in the early stages of L. chagasi infection are associated with the host's ability to prevent the progression of the infection to disease [6] . In the present study, IL-12, a at FundaÃ §Ã£o Oswaldo Cruz on February 26, 2014 http://jid.oxfordjournals.org/ Downloaded from nial therapy [15] . The evidence that IL-12 restores functions (cytotoxicity and IFN-y production) that are essential for control of leishmanial multiplication provides a rational basis for the use of IL-12 as an immunotherapeutic adjuvant for the treatment of visceral leishmaniasis.
